Table 2.
Univariate and multivariate analyses of OS and BCSS for the MBC variables included in the study before PSM
| Characteristics | Univariate | Multivariate | ||||||
|---|---|---|---|---|---|---|---|---|
| OS | BCSS | OS | BCSS | |||||
| HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age at diagnosis (< 60 as ref.) | ||||||||
| ≥ 60 | 1.92 (1.63–2.26) | < 0.01 | 1.23 (1.02–1.48) | < 0.05 | 1.81 (1.51–2.16) | < 0.01 | 1.36 (1.11–1.66) | < 0.001 |
| Race (white as ref.) | ||||||||
| Black | 1.02 (0.82–1.27) | 0.843 | 1.12 (0.88–1.43) | 0.364 | 1.01 (0.81–1.26) | 0.958 | 0.97 (0.76–1.25) | 0.828 |
| Others | 0.91 (0.65–1.26) | 0.583 | 0.98 (0.68–1.42) | 0.922 | 0.95 (0.69–1.32) | 0.763 | 0.97 (0.67–1.41) | 0.872 |
| Marital status (single as ref.) | ||||||||
| Married | 0.92 (0.74–1.14) | 0.449 | 0.78 (0.62–1.00) | < 0.05 | 0.93 (0.74–1.17) | 0.54 | 0.92 (0.71–1.18) | 0.506 |
| Grade (G1 as ref.) | ||||||||
| G2 | 1.23 (0.79–1.93) | 0.36 | 1.08 (0.61–1.92) | 0.786 | 1.08 (0.69–1.69) | 0.747 | 0.93 (0.52–1.65) | 0.801 |
| G3 | 1.5 (1.01–2.25) | < 0.05 | 1.77 (1.07–2.92) | < 0.05 | 1.18 (0.78–1.77) | 0.438 | 1.14 (0.69–1.9) | 0.605 |
| G4 | 1.94 (1.20–3.15) | < 0.01 | 2.50 (1.40–4.49) | < 0.01 | 1.56 (0.96–2.54) | 0.076 | 1.65 (0.92–2.98) | 0.095 |
| ER status (negative as ref.) | ||||||||
| Positive | 0.9 (0.73–1.12) | 0.36 | 0.88 (0.68–1.13) | 0.318 | 0.88 (0.68–1.14) | 0.316 | 0.8 (0.59–1.08) | 0.146 |
| PR status (negative as ref.) | ||||||||
| Positive | 0.8 (0.62–1.03) | 0.077 | 0.87 (0.66–1.16) | 0.339 | 0.81 (0.60–1.09) | 0.162 | 0.95 (0.68–1.34) | 0.779 |
| Stage T (≤ 5 cm as ref.) | ||||||||
| > 5 cm | 3.65 (3.11–4.28) | < 0.01 | 4.55 (3.79–5.46) | < 0.001 | 2.92 (2.44–3.49) | < 0.01 | 3.44 (2.79–4.24) | < 0.001 |
| Stage N (N0 as ref.) | ||||||||
| N1 | 1.79 (1.48–2.17) | < 0.01 | 2.35 (1.89–2.91) | < 0.001 | 1.55 (1.26–1.91) | < 0.01 | 1.78 (1.41–2.25) | < 0.001 |
| N2 | 3.45 (2.60–4.59) | < 0.01 | 4.01 (2.91–5.52) | < 0.001 | 2.55 (1.88–3.46) | < 0.01 | 2.49 (1.76–3.51) | < 0.001 |
| N3 | 3.86 (2.78–5.36) | < 0.01 | 5.03 (3.54–7.17) | < 0.001 | 2.91 (2.06–4.11) | < 0.01 | 3.33 (2.29–4.84) | < 0.001 |
| Breast operation (lumpectomy as ref.) | ||||||||
| Mastectomy | 2.56 (2.14–3.06) | < 0.01 | 2.75 (2.22–3.41) | < 0.001 | 1.3 (1.05–1.61) | < 0.05 | 1.32 (1.02–1.70) | < 0.05 |
| Chemotherapy (not done/unknown as ref.) | ||||||||
| Done | 0.62 (0.53–0.72) | < 0.01 | 0.99 (0.82–1.2) | 0.934 | 0.71 (0.60–0.85) | < 0.001 | 1.02 (0.82–1.27) | 0.848 |
| Radiotherapy (not done as ref.) | ||||||||
| Done | 0.62 (0.53–0.73) | < 0.001 | 0.73 (0.61–0.88) | < 0.001 | 0.73 (0.61–0.88) | 0.001 | 0.71 (0.58–0.88) | < 0.01 |
| Axilla LN operation (SLNB as ref.) | ||||||||
| ALND | 1.91 (1.62–2.25) | < 0.001 | 2.18 (1.79–2.65) | < 0.001 | 1.17 (0.97–1.42) | 0.096 | 1.14 (0.91–1.43) | 0.254 |
SLNB Sentinel lymph node biopsy, ALND axillary lymph node dissection
Significant results are in italic